Seraphina Therapeutics develops FA15™ (pentadecanoic acid, C15:0), a proprietary, vegan-friendly powdered ingredient marketed as fatty15, the company's first essential fatty acid supplement. The product is positioned to support cardiometabolic, immune, and liver health and is sold direct-to-consumer via a subscription platform. Seraphina plans to use new capital to expand its recurring DTC subscription business and to develop ingredient opportunities to fortify foods and beverages with C15:0. The company holds exclusive licensing rights to more than 30 U.S. and international patents, including USPTO patent 11,116,740 issued September 14, 2021, and has received GRAS status for FA15™. Early consumer adoption has been strong—Seraphina sold out its initial offering within six weeks—and retention metrics are high (more than 85% of customers renew; average monthly retention above 90%). The company is running a 12-week randomized, double-blind, placebo-controlled clinical trial to evaluate FA15™'s physiological effects. Seraphina Therapeutics developed fatty15, a consumer dietary supplement that delivers the pure fatty acid C15:0, which the company says promotes cellular resilience, enhances mitochondrial function, and activates receptors that regulate immunity, metabolism, mood, sleep and appetite. The C15:0 discovery was led by founders Drs. Eric and Stephanie Venn‑Watson following research that included studies of bottlenose dolphins; independent studies and a large-scale 14-year study of more than 14,000 people are cited linking higher C15:0 levels to better survival and health. Seraphina launched fatty15 as a vegan-, dairy- and gluten-free supplement sold in refillable glass bottles and is also advancing FA15™, a pure powder form of C15:0, as a food ingredient. The company says it continues to study C15:0 as a potential prescription therapeutic for related nutritional deficiencies. Seraphina is a spinout of Epitracker, Inc. and is headquartered in San Diego.

Total raised

$11M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2021